Search Bar & Filters
Found 30 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating CRD-4730, an oral drug, in a Phase 2 clinical trial involving adults with Catecholaminergic Polymorphic Ventricular Tachycardia CPVT. This study aims to assess the safety, tolerability, pharmacokinetics PK, and pharmacodynamics PD of CRD-4730. Participants will be part of a randomized, double-blind, placebo-controlled crossover study to better understand how CRD-4730 affects CPVT symptoms and treatment responses. Participants will be randomly assigned to one of three sequences in a 3-period crossover design. Each participant will receive two different doses of CRD-4730 and one matching placebo dose in a random order. The study includes multiple dosing periods where participants take tablets of CRD-4730 or placebo, allowing researchers to compare the effects and tolerability of different doses against placebo. During the trial, participants will undergo various assessments to monitor safety, drug levels, and effects on their condition from baseline to Day 101. The study involves close monitoring of heart function and other health measures, with outcome evaluations occurring at multiple timepoints. This will help researchers understand how the drug behaves in the body and its impact on CPVT symptoms, with the trial lasting several months to complete all study periods and follow-ups.
Actively Recruiting
Researchers are studying osivelotor, an oral drug, in adults and adolescents with sickle cell disease SCD. This Phase 23 trial aims to evaluate the safety, tolerability, effectiveness, and how the body processes the drug. The study includes participants with specific SCD types and looks to find the best dose while also comparing the drug against a placebo over 48 weeks. A long-term extension will assess ongoing safety and blood response. The study has three parts. Part A tested safety and dose in adults to find the optimal dose. Part B compares osivelotor to placebo in adults and adolescents over 48 weeks, with adults receiving a loading dose of 300 mg daily for 7 days then 150 mg daily, while adolescent doses will be defined later. An open-label extension allows participants who completed Part B to take osivelotor for up to two years or until it becomes commercially available. Participants will undergo screening to confirm eligibility, including stable hemoglobin levels and SCD history. During the trial, participants receive study medication or placebo and attend regular visits for monitoring. Researchers will assess safety, blood characteristics, and vaso-occlusive crisis events. The study includes careful monitoring of adverse events and blood tests, with a total participation period that may last up to two years for those in the extension phase.
Actively Recruiting
Researchers are evaluating the efficacy and safety of HBS-301 in adults aged 18 years and older who have idiopathic hypersomnia IH, a condition characterized by excessive daytime sleepiness EDS. This Phase 3 clinical trial is randomized, double-blind, and placebo-controlled, aiming to better understand how HBS-301 affects the severity of sleepiness and other IH symptoms compared to placebo. Participants will be randomly assigned to receive either HBS-301 tablets or matching placebo tablets once daily in the morning upon waking during an 8-week double-blind treatment period. After this, participants may choose to join an optional 1-year open-label extension where all receive HBS-301. The study begins with a screening and baseline period lasting up to 28 days, followed by 30 days of safety follow-up after treatment ends. During the trial, participants will have regular assessments including questionnaires measuring sleepiness severity using the Epworth Sleepiness Scale and other scales evaluating IH symptoms, sleep inertia, fatigue, cognition, quality of life, and work productivity. Safety monitoring includes tracking any adverse events throughout the 16 months of the study. Participants will be involved in scheduled visits for evaluations and treatment adherence, with the primary focus on changes in daytime sleepiness severity over the 8-week treatment period.
Actively Recruiting
This research aims to evaluate the effectiveness and safety of zanidatamab combined with a physicians choice of chemotherapy compared to trastuzumab combined with chemotherapy in treating adults with metastatic HER2-positive breast cancer who have either progressed on or cannot tolerate previous trastuzumab deruxtecan T-DXd treatment. Zanidatamab has shown promising results against various HER2-positive advanced tumors, including metastatic breast cancer, and may serve as a potential treatment option for these patients. The study also investigates patient-reported tolerability and physical functioning, as well as the pharmacokinetics and immune response to zanidatamab with chemotherapy. Participants will be randomly assigned to receive either zanidatamab or trastuzumab, each given by intravenous infusion alongside one of several chemotherapy options chosen by the physician eribulin, vinorelbine, gemcitabine, or capecitabine the latter is taken orally. Treatment will be administered according to the assigned group, and the study is open-label and multicenter, designed to compare these two treatment combinations in this patient population. During the study, participants will undergo regular assessments to monitor disease progression using imaging criteria RECIST version 1.1, evaluate survival, treatment response, and duration of response. Safety and side effects will be tracked through adverse event reporting and patient questionnaires on symptoms and physical function. Blood samples will be collected to study drug levels and immune reactions. Participants will be followed until disease progression, death, or for up to approximately 44 months for key outcomes, with overall survival monitored for up to about 80 months.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of expanded dosing schedules of Xywav in adults with narcolepsy or idiopathic hypersomnia IH. This Phase 3 trial compares different dosing regimens of Xywav to placebo to better understand treatment options for these sleep disorders. The study is sponsored by Jazz Pharmaceuticals and focuses on adult participants aged 18 to 75 years. Participants will undergo three treatment phases an open-label titration and optimization period OL-TOP lasting up to 12 weeks to establish a stable dose of Xywav, followed by a stable dose period SDP of 2 weeks where they continue the stable dose. Finally, participants enter a double-blind randomized withdrawal period DBRWP for 2 weeks, where they are randomly assigned to continue their Xywav dose or switch to placebo. The expanded dosing regimens include once-nightly or twice-nightly doses based on prior treatment and investigator decision. Total treatment duration can be up to 16 weeks. During the trial, participants will be regularly assessed for sleepiness using the Epworth Sleepiness Scale and other sleep-related measures. Researchers will also monitor cataplexy frequency, sleep quality, and symptom severity through questionnaires and clinical evaluations. Safety will be tracked by recording adverse events. Participants will be closely followed throughout the treatment periods, with outcome measures taken at the end of each phase to evaluate the effects of the expanded dosing regimens.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of clemizole hydrochloride EPX-100 as an additional treatment for children and adults with Dravet syndrome, a rare and severe form of epilepsy. This is a Phase 3, randomized, double-blind, placebo-controlled study conducted across multiple centers. The trial aims to assess whether clemizole HCl can help reduce the number of motor seizures experienced by participants whose seizures are not fully controlled by other anti-epileptic drugs AEDs. Participants will be randomly assigned to receive either clemizole HCl or a matching placebo twice daily during the double-blind phase, which includes a dose titration period followed by a maintenance period lasting up to 16 weeks. Those who complete this phase may have the option to join an open-label extension phase where they will receive clemizole HCl. The investigational treatments are given as oral solutions. Throughout the study, participants will be monitored for changes in the frequency of countable motor seizures over 28-day periods compared to their baseline seizure counts. Other assessments include seizure-free days, use of rescue AEDs, and clinician and caregiver evaluations of improvement. Safety will be closely followed by tracking adverse events. The overall participation may last up to 20 weeks or longer if the optional extension is chosen.
Actively Recruiting
Researchers are evaluating the effects of pitolisant on excessive daytime sleepiness EDS in patients aged 6 years and older with Prader-Willi syndrome. This Phase 3, randomized, double-blind, placebo-controlled global study aims to assess both the efficacy and safety of pitolisant. The study also investigates how pitolisant impacts irritable and disruptive behaviors, hyperphagia, and other behavioral issues such as social withdrawal, stereotypic behavior, hyperactivity, noncompliance, and inappropriate speech. The study includes an up to 45-day screening and baseline period followed by a double-blind treatment phase where participants are randomly assigned to receive either pitolisant tablets or matching placebo tablets once daily in the morning upon waking. This treatment period includes in-person visits on Days 29, 57, and 77. Afterward, participants may enter an optional open-label extension period receiving pitolisant, with visits on Days 113, 260, and 441. Follow-up visits occur 15 and 30 days after the last dose during both treatment periods. Participants will undergo various assessments including patient-reported measures of sleep-related impairment and caregiver and clinical impressions of sleepiness and behavior at baseline and the end of the double-blind phase. Behavioral scales like the Aberrant Behavior Checklist and Hyperphagia Questionnaire are used to evaluate changes. Safety is monitored by tracking adverse events throughout the study. The total duration of participation may extend beyond one year for those joining the extension period.
Actively Recruiting
Researchers are evaluating the combined use of finerenone and empagliflozin compared to usual care to assess their safety and effectiveness in patients hospitalized with heart failure. This international, randomized, controlled, open-label trial aims to study an early, intensive management approach for heart failure treatment. Participants will be assigned to receive either the combination of oral finerenone plus oral empagliflozin or usual care. The study focuses on treatment during hospitalization and shortly after, comparing these approaches to understand the clinical benefits and risks over a six-month period. During the trial, participants will be monitored for clinical outcomes including serious adverse events and events leading to treatment discontinuation. Researchers will measure heart failure events, symptom changes using the Kansas City Cardiomyopathy Questionnaire, and overall survival up to six months. Safety and efficacy data will be collected throughout the study period ending in November 2027.
Actively Recruiting
Researchers are evaluating the effects of biweekly XEMBIFY combined with Standard Medical Treatment SMT over one year in adults with hypogammaglobulinemia HGG who have B-cell Chronic Lymphocytic Leukemia CLL, Multiple Myeloma MM, or Non-Hodgkin Lymphoma NHL. The study aims to determine if this combination reduces the yearly rate of major bacterial infections compared to a placebo plus SMT. This Phase 3 trial is randomized, double-blinded, and placebo-controlled to ensure reliable results. Participants will receive either XEMBIFY or a placebo via subcutaneous infusion. The treatment starts with a loading dose of 150 mgkgday given daily for five days in the first week, followed by biweekly infusions of 300 mgkg from Week 3 through Week 51. Along with the study drug or placebo, all participants will continue to receive their usual standard medical treatments and supportive care needed during the trial. During the study, participants will be regularly monitored to assess the rate and timing of major bacterial infections and other infection-related outcomes. Researchers will track hospitalizations, antibiotic use, and overall infection rates up to Week 51. Safety and pharmacokinetics of the treatment will also be evaluated throughout. The total participation period lasts about one year, during which participants will have scheduled visits for treatment administration and assessments.
Actively Recruiting
Researchers are conducting an observational study to understand the safety of BIIB141, also called omaveloxolone or SKYCLARYS, in people with Friedrichs Ataxia FA who took this drug during pregnancy andor breastfeeding. The study aims to assess any risks to the mother and baby, including major and minor birth defects, maternal complications, and health effects on the baby up to one year after birth. This research will collect health information without changing participants regular medical care. Participants include women with FA exposed to omaveloxolone anytime from shortly before conception through pregnancy and breastfeeding up to one year after their baby is born or until weaning. The study involves collecting both new and past data from participants routine healthcare visits. The study will last at least 10 years to gather comprehensive information about pregnancy outcomes and infant health. During the study, researchers will monitor various outcomes such as the number of major and minor birth defects, gestational diabetes, pre-eclampsia, fetal loss, premature birth, infant growth and development, hospitalizations, and infections. Participants will join after consenting and remain in the study for up to one year after their childs birth unless they choose to leave earlier. The study collects data from routine care visits and does not involve administering any treatment.
1-10 of 30
1